Triazoles | Broad Institute

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Ott CJ, Federation AJ, Schwartz LS, et al. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 2018;34(6):982-995.e7. doi:10.1016/j.ccell.2018.11.001PubMed DOI Google Scholar

In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.

Mandt REK, Lafuente-Monasterio MJ, Sakata-Kato T, et al. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model. Sci Transl Med. 2019;11(521). doi:10.1126/scitranslmed.aav1636Google Scholar PubMed DOI

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer.

Adeegbe DO, Liu S, Hattersley MM, et al. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res. 2018;6(10):1234-1245. doi:10.1158/2326-6066.CIR-18-0077PubMed DOI Google Scholar

Macrocycloadditions leading to conformationally restricted small molecules.

Looper RE, Pizzirani D, Schreiber SL. Macrocycloadditions leading to conformationally restricted small molecules. Org Lett. 2006;8(10):2063-6. doi:10.1021/ol0604724Google Scholar PubMed DOI

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, Tekle GE, Bellini E, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046-1054. doi:10.1038/nm.4372Google Scholar PubMed DOI

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.

Iniguez AB, Alexe G, Wang EJ, et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018;34(6):922-938.e7. doi:10.1016/j.ccell.2018.11.005PubMed DOI Google Scholar

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.

Bandopadhayay P, Piccioni F, O’Rourke R, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019;10(1):2400. doi:10.1038/s41467-019-10307-9PubMed DOI Google Scholar

Accessing skeletal diversity using catalyst control: formation of n and n + 1 macrocyclic triazole rings.

Kelly AR, Wei J, Kesavan S, et al. Accessing skeletal diversity using catalyst control: formation of n and n + 1 macrocyclic triazole rings. Org Lett. 2009;11(11):2257-60. doi:10.1021/ol900562uPubMed DOI Google Scholar

Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-23. doi:10.1158/2159-8290.CD-12-0418PubMed DOI Google Scholar

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777-90. doi:10.1016/j.ccr.2013.11.003PubMed DOI Google Scholar